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The aim of this paper is to investigate whether Shen-fu injection (SFI), a traditional Chinese medicine, could attenuate myocardial
ischemia-reperfusion (MI/R) injury in diabetes. Streptozotocin-induced diabetic rats were randomly assigned to the Sham, I/R,
SFI preconditioning, and SFI plus wortmannin (a phosphatidylinositol 3-kinase inhibitor) groups. After the treatment, hearts
were subjected to 30min of coronary artery occlusion and 2h reperfusion except the Sham group. Myocardial infarct size and
cardiomyocytes apoptosis were increased signiﬁcantly in MI/R group as compared with the Sham group. SFI preconditioning
signiﬁcantly decreased infarct size, apoptosis, caspase-3 protein expression, MDA level in myocardial tissues, and plasma level of
CK and LDH but increased p-Akt, p-eNOS, bcl-2 protein expression, and SOD activity compared to I/R group. Moreover, SFI-
induced cardioprotection was abolished by wortmannin. We conclude that SFI preconditioning protects diabetic hearts from I/R
injury via PI3K/Akt-dependent pathway.
1.Introduction
Epidemiological and pathological data show that diabetes
is a major risk for cardiovascular morbidity and mortality
[1, 2]. Ischemic coronary artery disease is responsible for
three-quarters of diabetes-related death [3]. Approximately
50% of diabetic patients die 5 years after a myocardial
infarction, double the rate found in nondiabetic patients
[4, 5]. The poor prognosis may be at least in part because of
an increase in the myocardial injury in response to ischemia
and reperfusion [5].
Shen-Fu injection (SFI),an extractof traditional Chinese
herbs, has been routinely used in treating cardiac diseases for
a long time in China. We have previously demonstrated that
SFI could attenuate myocardial ischemia-reperfusion (MI/R)
injury and enhance postoperative myocardial functional
recovery in patients undergoing cardiopulmonary bypass
heart operations [6]. The beneﬁcial eﬀects of SFI may
attributetoalleviatingthecellinjuriesduringischemiareper-
fusion. Moreover, the mechanism of SFI’s cardioprotection
remains to be elucidated. The eﬀects of SFI preconditioning
on diabetic rats following ischemia-reperfusion injury is not
well understood.
In the present study, we aimed to investigate whether SFI
protects diabetic rats from I/R injury and, more importantly,
to explore the underlying mechanisms.
2.MaterialsandMethods
2.1. Experimental Animals. The experimental protocol used
in this study was reviewed and approved by the Animal Care
and Use Committee of Wuhan University and in accordance
with the National Institutes of Health guidelines for the use
of experimental animals. Male Sprague-Dawley (SD) rats
weighing 240g to 280g were provided by the Experimental2 Journal of Biomedicine and Biotechnology
Animal Center of Wuhan University. All animals were
allowed free access to food and water and maintained at 22–
24 degree Celsius under a cycle of 12h: 12h light-dark.
2.2. Drugs and Reagents. Streptozotocin (STZ), triphenylte-
trazoliumchloride(TTC),Evansblue(EB),andwortmannin
were purchased from Sigma (St. Louis, MO, USA). Shen-fu
injection (contains 0.9mg ginsenosides and 0.1mg aconite
alkaloid per milliliter) was produced by Ya’an Sanjiu Phar-
maceutical Co., Ltd., China.
2.3. Induction of Diabetes. Experimental diabetes was
induced in male SD rats by intravenous injection of STZ
dissolved in 0.1mol/L citrate buﬀer (pH 4.5) at a dose of
65mg/kg. Three days after STZ injection, hyperglycemia
was documented by measuring the glucose content of
tail vein blood with OneTouch glucometer (Johnson and
Johnson, USA). Rats with blood glucose concentrations ≥
16.7mmol/L were considered to be diabetic.
2.4. Surgical Preparations. All animals were anesthetized
with IP injection of pentobarbital sodium (50mg/kg) and
ventilated with room air. A cannula was inserted into the
left femoral vein for administration of drugs and into
the left carotid artery for measurement of blood pressure,
respectively. Limb lead II of the ECG was used to measure
the heart rate. A fourth intercostal space thoracotomy was
performed, and the pericardium was excised to expose the
heart. The left anterior descending coronary artery (LAD)
was ligated 2mm above the left auricle by a 6–0 silk suture
to induce regional myocardial ischemia. After 30min of
ischemia, the ligature was loosened to allow reperfusion
for 2h. Sham-operated rats underwent the same surgical
procedures, without tying the 6–0 silk suture. At the end of
reperfusion, rats were killed, and parts of the anterior wall
of the left ventricular myocardium near the cardiac apex and
blood samples were obtained for further analysis.
2.5. Experimental Protocol. Eight weeks after STZ adminis-
tration, rats were randomly allocated into 4 groups as fol-
lows: Group 1 rats (Sham), received vehicle (10ml/kg saline)
but no tightening of the coronary sutures, Group 2 rats
(I/R), received vehicle (10ml/kg saline) and were subjected
to 30min of ischemia followed by 2h of reperfusion, Group
3 rats (SFI), treated with 10ml/kg SFI and were subjected
to 30min of ischemia followed by reperfusion, Group 4
rats (SFI+WOR), treated with 10ml/kg SFI plus a speciﬁc
inhibitor of PI3K wortmannin and were subjected to 30min
of ischemia followed by reperfusion.Wortmannin (15ug/kg)
was administered 20min before coronary ischemia and
reperfusion, 10min before the administration of SFI. The
time course of the experiments is depicted in Figure 1.T h e
dose of SFI and wortmannin were based on previous studies
of myocardial ischemia-reperfusion injury [7, 8].
2.6. Hemodynamics. Hemodynamic measurements included
heart rate (HR) and mean arterial pressure (MAP). The rate
pressure product (RPP) was calculated as the product of
the heart rate and the peak mean arterial pressure. These
parameters were continuously measured during baseline,
30min into ischemia and at 2h of reperfusion.
2.7. Determination of Infarct Size. At the end of the 2-hour-
reperfusion period, the ligature around the coronary artery
was retied again, and 2ml of 0.25% EB dye was injected
into the aorta to map the normally perfused region of the
heart. The myocardial area at risk (AAR) for infarction was
delineatedbytheareaofmyocardiumnotdyed.Thepresence
of EB was used to identify the area that was not subjected to
the ischemia. Rat hearts were rapidly excised and frozen at
−20 degree Celsius and then sliced into 2mm thick sections
perpendicular to the heart base-apex axis using a heart slice
chamber. The slices were incubated in 1% TTC in pH 7.4
buﬀer for 15min at 37 degree Celsius to distinguish the
viable myocardium from the necrotic. The viable tissue was
stained red by TTC, while the infarct portion not taking up
TTC stain remained pale. Morphometric measurements of
the AAR and infarct area (IA) in each slice were performed
with a scanner (Epson, v30, Japan) and an image analysis
system (Image-Pro plus; Media Cybernetics, Bethesda, MA).
The percentage of ratios of AAR versus left ventricle (LV)
(AAR/LV) and IA versus AAR (IA/AAR) were calculated.
2.8. Plasma Creatine Kinase Isoenzyme and Lactate Dehydro-
genase Assay. Arterial blood samples were collected at the
endofreperfusionandcentrifugedat3000rpm,for10minat
4 degree Celsius. Two speciﬁc marker enzymes, including the
creatine kinase isoenzyme (CK) and lactate dehydrogenase
(LDH)fromtheplasma,weremeasuredbyusingcommercial
kits (Beijing Kemeidongya Biotechnology Ltd., China). The
content of these marker enzymes was expressed as U/L.
2.9. Determination of Myocardial Apoptosis. Terminal
deoxynucleotidyl nick-end labeling (TUNEL) assay was
used to assess myocardial apoptosis with an apoptosis
detection kit (Roche, Basel, Switzerland). TUNEL-positive
cardiomyocytes in the ischemic myocardium were carefully
evaluated under double-blind conditions. The percentage
of TUNEL-positive cells was determined by dividing the
number of positive-staining nuclei by the total number of
nuclei of the cell.
2.10. Western Blot Analysis. Myocardium tissue samples
(100mg) were lysed with lysis buﬀer. After sonication,
the lysates were centrifuged, and protein concentration
was determined with BCA protein assay kit (Beyotime
Biotech Inc, Jiangsu, China). Protein extracts were separated
by electrophoresis on SDS-PAGE and then transferred
onto a polyvinylidene diﬂuoride (PVDF) membrane. The
membranes were incubated in 5% dry milk for 1h and
then incubated with the following primary antibodies:
phosphorylated Akt (p-Akt, Ser473), Akt, phosphorylated
endothelial nitric oxide synthase (p-eNOS, Ser1177), eNOS,
caspase-3 (Cell Signaling), Bcl-2, and glyceraldehyde-3-
phosphate dehydrogenase (GADPH, Santa Cruz). Subse-
quently,themembraneswerewashedandincubatedwiththeJournal of Biomedicine and Biotechnology 3
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Figure 1: Experimental protocols. Diabetic rats were subjected to 30min of coronary artery occlusion followed by 2h of reperfusion. SFI
was applied 10 minutes before ischemia. Wortmannin was applied 20 minutes prior to ischemia. I/R: ischemia/reperfusion; SFI: Shen-fu
injection; WOR: wortmannin.
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Figure 2: Myocardial infarct size in Sham-operated rats or in
rats subjected to 30min ischemia followed by 2h of reperfusion.
The blue-stained areas represent nonischemic tissue, and red-
stained areas represent the area at risk. Pale areas indicate infarct
areas. Values presented are mean ± SEM. AAR: area at risk;
IA: infarct area; I/R: ischemia/reperfusion; SFI: Shen-fu injection;
WOR: wortmannin. n = 6, ∗P<. 05 versus Sham, #P<. 05 versus
I/R, and αP<. 05 versus SFI.
correspondinghorseradishperoxidase-conjugatedsecondary
antibody. The protein bands were visualized with ECL plus
reagent (Pierce Biotechnology Inc., Rockford, IL). GADPH
was chosen as a loading control to further assure the same
volume for all the samples.
2.11. Activity of Superoxide Dismutase and the Level of Malon-
dialdehyde in Myocardial Tissues. At the end of reperfusion,
the myocardial supernatant was isolated from ischemia heart
tissue samples by centrifugation at 4000rpm for 10min at
4◦C. The superoxide dismutase (SOD) activity and mal-
ondialdehyde (MDA) level were measured by colorimetric
analysis using a spectrophotometer with the associated
detection kits (Jiancheng, Nanjing, China), respectively.
2.12. Statistical Analysis. A l lv a l u e sa r ep r e s e n t e da sm e a n±
SEM. Diﬀerences between groups were determined by using
one-way ANOVA Analysis followed by Bonferroni’s post hoc
test. A value of P<. 05 was considered to be statistically
signiﬁcant.
3. Results
3.1. Basic Parameters. There were no major diﬀerences
between groups in terms of blood glucose, body weight, and
the heart to body weight ratio before the MI/R (Table 1).
3.2. Systemic Hemodynamics. There were no signiﬁcant
diﬀerences in HR, MAP, and RRP among groups during
coronary artery occlusion and reperfusion.
3.3. Eﬀect of SFI on Myocardial Infarct Size. To examine
whether SFI treatment reduces the myocardial injury fol-
lowing I/R in diabetic hearts, myocardial infarct size was
measured. The representative images of AAR and IA from
each group were shown in Figure 2.T h i r t ym i n u t e so f
ischemiafollowedby2hofreperfusionresultedinsigniﬁcant
myocardial infarction in I/R rats compared with that in
Sham-operatedones(53.8±2.2%versusSham,P<. 05).The
infarct size was signiﬁcantly decreased with the treatment of
SFI (42.4 ± 6.7% versus I/R, P<. 05). Interestingly, admin-
istration of wortmannin abolished SFI-induced reduction in
infarct size, and infarct was similar to I/R group (Figure 2).
These results provided direct evidence that SFI reduces
myocardial injury following I/R via PI3K/Akt-dependent
signaling pathway. No signiﬁcant diﬀerence in AAR was
found between the four groups (P>. 05).
3.4. Eﬀect of SFI on Plasma CK and LDH Activities in Diabetic
Rats. To determine whether SFI may also reduce myocardial
cellular damage induced by MI/R, the activities of CK and
LDH that are indices of myocardial cellular injury were4 Journal of Biomedicine and Biotechnology
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Figure 3: Plasma creatine kinase (CK) and lactate dehydrogenase (LDH). I/R: ischemia/reperfusion; SFI: Shen-fu injection; WOR:
wortmannin. Values presented are mean ± SEM. n = 8, ∗P<. 05 versus Sham, #P<. 05 versus I/R, and αP<. 05 versus SFI.
Table 1: Basic parameters of the rats.
Basic parameters Sham I/R SFI SFI+WOR P
Blood glucose (mmol/l) 22.8 ±1.12 4 .9 ±1.52 4 .3 ±1.42 1 .8 ±1.1. 3 2
Body weight (g) 239.9 ± 6.3 224.5 ±9.7 233.3 ±9.0 243.1 ±7.9. 4 1
Heart to body weight ratio (mg/g) 2.93 ±0.18 3.13 ±0.12 2.85 ±0.10 3.10 ±0.09 .37
Values presented are mean ± SEM. I/R: ischemia/reperfusion; SFI: Shen-fu injection; WOR: wortmannin. n = 16 in each group.
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Figure 4: Representative photomicrographs of TUNEL staining
from Sham, I/R, SFI, and SFI+WOR groups, respectively (×400).
I/R: ischemia/reperfusion; SFI: Shen-fu injection; WOR: wortman-
nin. Values presented are mean ± SEM. n = 4, ∗P<. 05 versus
Sham, #P<. 05 versus I/R, and αP<. 05 versus SFI.
measured at the end of reperfusion. In comparison with
Shamgroup,I/RcausedasigniﬁcantincreaseinCKandLDH
(both having P<. 05, Figure 3). However, CK and LDH
activities were decreased in rats treated with SFI compared
with I/R group (both having P<. 05). Pretreatment with
wortmannin signiﬁcantly blunted the SFI-induced decrease
of plasma CK and LDH (both having P<. 05 versus SFI
group).
3.5. Eﬀect of SFI on Myocardium Apoptosis in Diabetic Rats.
As shown in Figure 4, the percentage of TUNEL-positive
myocyte nuclei was signiﬁcantly increased in the I/R group
compared with the Sham group (P<. 05). SFI treatment
reduced TUNEL-positive cells in hearts subjected to MI/R
(versus I/R group, P<. 05). Pretreatment of the rats with
wortmanninattenuatedtheeﬀectofSFIinreducingTUNEL-
positive cells.
3.6. Eﬀect of SFI on the Protein Phosphorylation of Akt
in Diabetic Rats. After 2h of reperfusion, no signiﬁcant
changes were identiﬁed in total Akt expression among the
Sham, I/R, SFI, and SFI+WOR groups (Figures 5(a) and
5(b)). Akt phosphorylation has been demonstrated to reﬂect
Aktactivation.TreatmentwithSFIsigniﬁcantlyincreasedthe
expression of p-Akt (P<. 05, SFI versus I/R). In addition,
the eﬀect of SFI on Akt phosphorylation was completely
abolished by treatment with wortmannin, a speciﬁc PI3K
blocker (P<. 0 5 ,S F Iv e r s u sS F I + W O R )( F i g u r e5(c)).
3.7. Eﬀect of SFI on the Protein Phosphorylation of eNOS in
Diabetic Rats. It has been reported that eNOS is a substrate
for Akt and NO production following Akt-evoked eNOS
phosphorylation [9]. We therefore attempted to determine
whether eNOS phosphorylation contributes to SFI-induced
cardioprotection. As illustrated in Figure 6, there was no
signiﬁcant diﬀerence in eNOS expression among diﬀerent
groups, while treatment with SFI resulted in signiﬁcantJournal of Biomedicine and Biotechnology 5
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Figure 5: Immunoblots and graphs showing the protein levels and fold increases in total and phosphorylated Akt from Sham, I/R, SFI, and
SFI+WOR groups, respectively. I/R: ischemia/reperfusion; SFI: Shen-fu injection; WOR: wortmannin. Values presented are mean ± SEM.
n = 6, #P<. 05 versus I/R, and αP<. 05 versus SFI.
expression of p-eNOS (P<. 05, I/R versus SFI). Most
importantly, to explore whether the increase in p-eNOS was
related to PI3K/Akt pathway, diabetic rats were pretreated
with wortmannin. The results showed that treatment with
wortmannin completely abrogated the increase in p-eNOS
(P<. 05, SFI versus SFI+WOR).
3.8. Eﬀect of SFI on Bcl-2 and Caspase-3 Cleavage in
Diabetic Rats. We measured antiapoptotic protein Bcl-2 and
proapoptotic protein caspase-3 expression in the present
study. As shown in Figure 7, SFI enhanced the expression of
Bcl-2 compared to the saline-treated I/R rats. Pretreatment
with wortmannin abolished the eﬀect of SFI-induced Bcl-
2 upregulation and decreased it to a level similar to the I/R
group.
Caspase-3isapivotalmediatorofapoptosis,andmyocar-
dial caspase-3 activity is suggested as a marker of MI/R
myocyte apoptosis [10]. Caspase-3 normally exists as a 32-
kDa inactive precursor that is cleaved proteolytically to
an active p17 subunit when cells are induced to undergo
apoptosis. To determine whether caspase-3 was activated, we
detected the cleaved (activate) caspase-3 protein by Western
blotting. As shown in Figure 7, there were no changes in
total (inactivate) caspase-3 proteins among the 4 groups.
The activate caspase-3 was signiﬁcantly increased after MI/R
as compared with that in Sham group (I/R versus Sham,
P<. 05). The activate caspase-3 was decreased in SFI group
(Figure 7(d), P<. 05, I/R versus SFI), and pretreatment with
wortmannin abolished the caspase-3 activation.
3.9. Eﬀect of SFI on Activity of SOD and Level of MDA in
Diabetic Rats. Data are shown in Figure 8. Compared with
the Sham group, the I/R-induced injury was manifested by
a signiﬁcant increase in MDA and decrease in SOD. The
administration of SFI caused a signiﬁcant decrease in the
MDA content and increase in SOD enzyme activity com-
pared with the I/R group. Moreover, SFI-induced changes in
MDA and SOD were reverted by wortmannin treatment.
4. Discussion
Several important observations were made in the present
study. First, we have shown that SFI treatment attenuated
MI/R injury in diabetic rats as evidenced by attenuated
myocardial apoptosis and reduced infarct size in a PI3K/Akt-
dependent manner. Second, Akt-evoked eNOS phosphory-
lation signiﬁcantly contributes to SFI-induced cardioprotec-
tion.Inaddition,wehaveprovidedevidencethatSFIprotects6 Journal of Biomedicine and Biotechnology
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Figure 6: Immunoblots and graphs showing the protein levels and fold increases in total and phosphorylated eNOS from Sham, I/R, SFI,
and SFI+WOR groups, respectively. I/R: ischemia/reperfusion; SFI: Shen-fu injection; WOR: wortmannin. Values presented are mean ±
SEM. n = 6, #P<. 05 versus I/R, and αP<. 05 versus SFI.
the diabetic hearts from oxidative stress even in the absence
of ischemia/reperfusion.
Shen-fu injection is composed of Ginseng and Fuzi.
Previous data from experimental studies have demonstrated
that SFI has signiﬁcant protective eﬀects on cardiovascular
system. Zheng et al. studied myocardial infarction and
reperfusion injury in an in vivo rat model and discovered
that SFI reduced the size of infarction and improved
the pathologic changes of myocardium during ischemia
reperfusion [8]. In cell culture model, Wang et al. reported
that SFI can prevent cardiomyocytes apoptosis induced
by hypoxia/reoxygenation injury via upregulation of Bcl-2
protein levels and downregulation of caspase-3 [11]. One
of our recent studies showed that the SFI reduced MI/R
injury in congenital heart patients also supported these
conclusions.The SFI-induced inactivation of caspase-3 may
lead to inhibition of myocardial apoptosis after MI/R. It was,
therefore, important to study whether SFI can also aﬀord
similar cardioprotection in hearts from diabetic subjects.
Among numerous signaling pathways involved in regu-
lation of cell survival, PI3K/Akt signaling pathway plays a
crucial role in protecting the myocardium from MI/R injury
[12–14]. Previous studies have demonstrated that pharma-
cologic preconditioning fails to induce cardioprotection in
STZ-induced diabetic animals, and PI3K/Akt pathway was
impaired in diabetic rats [15–17]. In our present study, we
detected signiﬁcant activation of survival pathway as evi-
denced by robust phosphorylation of Akt in SFI-treated dia-
betic myocardium following ischemia reperfusion. However,
expression of p-Akt was undetectable when wortmannin
w a sg i v e na l o n gw i t hS F It h e r a p y .I ts e e m st h a tS F Ii n d u c e s
cardioprotective eﬀects through the activation of PI3K/Akt
pathway in diabetic rats. The protein expression of PI3K was
not assessed in the current study. Further investigation will
be needed to explore whether SFI act directly on upstream
signaling pathways.
HowactivationofAktincreasescardiomyocyteresistance
to MI/R injury in diabetic rats is incompletely understood.
Strong evidence shows that eNOS is an important target
of Akt and eNOS functions as an important cardiovascular
protective molecule [9, 18, 19]. Recent studies show that
increased expression of p-Akt and p-eNOS alleviates the
IR injury in the diabetic myocardium [17, 19]. Our study
showed that SFI treatment resulted in an enhanced level p-
eNOS which was signiﬁcantly higher than that of saline-
treated I/R group. These results suggest that SFI-induced
cardioprotective eﬀects are mediated through Akt-induced
eNOS phosphorylation. eNOS is the source of NO and isJournal of Biomedicine and Biotechnology 7
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Figure 7: Immunoblots and graphs showing the protein levels of bcl-2 and caspase-3 from Sham, I/R, SFI, and SFI+WOR groups,
respectively. I/R: ischemia/reperfusion; SFI: Shen-fu injection; WOR: wortmannin. Values presented are mean ± SEM. n = 6, ∗P<. 05
versus Sham, #P<. 05 versus I/R, and αP<. 05 versus SFI.
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Figure 8:Malondialdehyde(MDA)andsuperoxidedismutase(SOD).I/R:ischemia/reperfusion;SFI:Shen-fuinjection;WOR:wortmannin.
Values presented are mean ± SEM. n = 6, ∗P<. 05 versus Sham, #P<. 05 versus I/R, and αP<. 05 versus SFI.
important in regulation of vasodilatation, vascular remod-
eling, cardiac structure, and angiogenesis [20, 21]. It has
been shown that NO inhibits apoptosis both in vitro and
in vivo [9, 22]. NO can rapidly elevate Bcl-2 expression at
protein and mRNA level [23–25]. The level of Bcl-2 protein
has been suggested to determine cardiac myocyte survival or
death after ischemia and reperfusion [9, 25–27]. The release
of Bcl-2 during ischemia-reperfusion injury has been proven
to prevent apoptosis by blocking the release of cytochrome
c from the mitochondria and ameliorating the activation8 Journal of Biomedicine and Biotechnology
of caspase-3 [25, 28]. Caspase-3 is an intracellular cysteine
protease that is one of the key executioners of apoptosis
[8, 29, 30]. As expected, pretreatment with SFI signiﬁcantly
inhibited the activation of subsequent eﬀector caspase-3.
The SFI-induced inactivation of caspase-3 may lead to its
inhibition of myocardial apoptosis after MI/R.
On the other hand, numerous studies have shown that
the production of reactive oxygen species (ROS) is increased
in diabetes. Excessive ROS leads to inactivation of NO
and thus impaired NO-dependent cardioprotection [31–
33]. MDA is a marker of lipid peroxidation that occurs
as a result of the damaging eﬀects of ROS, and SOD is a
cellular ROS scavenger [34, 35]. In our study, following SFI
treatment,wefoundthattheincreaseofSODactivityandthe
decrease of MDA production may have provided extensive
protection to diabetic hearts and facilitated NO-dependent
cardioprotection. Considerable evidence demonstrates that
SFI has signiﬁcant protective eﬀects in diﬀerent organs.
Qian et al. reported that SFI inhibited endotoxin-induced
pulmonary inﬂammation in vivo [36]. SFI is also reported
to have protective eﬀect on gastrointestinal microcirculation
after myocardial IR injury in rabbits, in a dose-independent
manner [37]. Furthermore, SFI can inhibit the production
of oxygen free radical and decrease apoptosis of liver cell in a
liver graft model [38].
There are several limitations with the present study that
should be mentioned. First, the cardiac protective eﬀect
of SFI in nondiabetic rats was not investigated in our
study. It is reported that SFI can protect normal rats from
MIR injury, with the increase of SOD and decrease of
t h eM D Ac o n t e n t s[ 8]. Therefore, it seems that SFI has
similarbeneﬁcialeﬀecttobothnondiabeticanddiabeticrats.
Second, we did not directly measure the cardiac function
during the experiment as the primary goal of the study is
to explore the signaling pathway that may involve Shen-fu
cardioprotection. However, we have collected hemodynamic
parameters, including HR, MAP, and RPP, which indirectly
indicate that SFI has no major eﬀect on cardiac function.
Third, the amount of NO was not monitored in this study.
NO is produced from eNOS, neuronal NOS (nNOS), and
inducible NOS (iNOS) in the heart. Further study will be
needed to explore whether Shen-Fu injection can modulate
the NO production as well as the underling mechanism.
In summary, the current study demonstrated that
SFI could protect cardiomyocytes against MI/R injury
and inhibits apoptosis in diabetic rats via activating
PI3K/Akt/eNOS signaling pathway.
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